{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:22:26Z","timestamp":1778865746629,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.vaccine.2020.01.091","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T17:49:24Z","timestamp":1581097764000},"page":"2542-2550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Bacteriophage Q\u03b2 virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-0842","authenticated-orcid":false,"given":"Rupsa","family":"Basu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukai","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenna","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7484-2081","authenticated-orcid":false,"given":"Ebenezer","family":"Tumban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.091_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094401","article-title":"Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line","volume":"9","author":"Wagner","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.091_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205058","article-title":"Human and entomologic investigations of chikungunya outbreak in Mandera, Northeastern Kenya, 2016","volume":"13","author":"Konongoi","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.091_b0015","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3899\/jrheum.171237","article-title":"Chikungunya in Brazil: Rheumatologists on the Front Line","volume":"45","author":"Amaral","year":"2018","journal-title":"J Rheumatol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0020","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1586\/erv.12.84","article-title":"Chikungunya virus and prospects for a vaccine","volume":"11","author":"Weaver","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.01.091_b0025","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"Silva","year":"2017","journal-title":"J Clin Invest."},{"key":"10.1016\/j.vaccine.2020.01.091_b0030","doi-asserted-by":"crossref","unstructured":"Morrison CR, Plante KS, Heise MT. Chikungunya Virus: Current Perspectives on a Reemerging Virus. Microbiol Spectr. 2016;4.","DOI":"10.1128\/microbiolspec.EI10-0017-2016"},{"key":"10.1016\/j.vaccine.2020.01.091_b0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/0972-9062.242561","article-title":"Chikungunya virus outbreak in Sint Maarten: Long-term arthralgia after a 15-month period","volume":"55","author":"Peters","year":"2018","journal-title":"J Vector Borne Dis."},{"key":"10.1016\/j.vaccine.2020.01.091_b0040","doi-asserted-by":"crossref","first-page":"11644","DOI":"10.1128\/JVI.01432-14","article-title":"Reemergence of chikungunya virus","volume":"88","author":"Morrison","year":"2014","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1590\/0037-8682-0479-2016","article-title":"Alert: Severe cases and deaths associated with Chikungunya in Brazil","volume":"50","author":"Brito","year":"2017","journal-title":"Rev Soc Bras Med Trop."},{"key":"10.1016\/j.vaccine.2020.01.091_b0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2017.09.012","article-title":"A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9","volume":"147","author":"Zhai","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.vaccine.2020.01.091_b0055","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1016\/j.vaccine.2008.07.054","article-title":"Chimeric alphavirus vaccine candidates for chikungunya","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.091_b0060","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","article-title":"A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus","volume":"31","author":"Brandler","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.091_b0065","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2020.01.091_b0070","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.01.091_b0075","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","article-title":"Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218","volume":"62","author":"Edelman","year":"2000","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.vaccine.2020.01.091_b0080","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/infdis\/jiu014","article-title":"Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose","volume":"209","author":"Roy","year":"2014","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.01.091_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002719","article-title":"Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design","volume":"8","author":"Gardner","year":"2014","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.vaccine.2020.01.091_b0090","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1128\/JVI.06449-11","article-title":"Attenuation of Chikungunya virus vaccine strain 181\/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein","volume":"86","author":"Gorchakov","year":"2012","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0095","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/249640","article-title":"Replication of alphaviruses: a review on the entry process of alphaviruses into cells","volume":"2011","author":"Leung","year":"2011","journal-title":"Adv Virol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/emmm.201200213","article-title":"Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein","volume":"4","author":"Kam","year":"2012","journal-title":"EMBO Mol Med."},{"key":"10.1016\/j.vaccine.2020.01.091_b0105","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.4049\/jimmunol.1300304","article-title":"An essential role of antibodies in the control of Chikungunya virus infection","volume":"190","author":"Lum","year":"2013","journal-title":"J Immunol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003445","article-title":"Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients","volume":"9","author":"Kam","year":"2015","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.vaccine.2020.01.091_b0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","article-title":"The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?","volume":"17","author":"Slingluff","year":"2011","journal-title":"Cancer J."},{"key":"10.1016\/j.vaccine.2020.01.091_b0120","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","article-title":"Peptide Vaccine: Progress and Challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2020.01.091_b0125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0130","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.vaccine.2018.01.056","article-title":"Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells","volume":"36","author":"Basu","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.091_b0135","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.vaccine.2014.06.054","article-title":"Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing","volume":"32","author":"Tyler","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.091_b0140","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1016\/j.vaccine.2006.05.059","article-title":"Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses","volume":"24","author":"Chackerian","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.091_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023310","article-title":"A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2","volume":"6","author":"Tumban","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.091_b0150","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1128\/JVI.01672-14","article-title":"Residue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice","volume":"88","author":"Ashbrook","year":"2014","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ajpath.2010.11.018","article-title":"A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence","volume":"178","author":"Morrison","year":"2011","journal-title":"Am J Pathol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0160","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00816-17","article-title":"Mutations in the E2 Glycoprotein and the 3' Untranslated Region Enhance Chikungunya Virus Virulence in Mice","volume":"91","author":"Hawman","year":"2017","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003312","article-title":"Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus","volume":"9","author":"Pal","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2020.01.091_b0170","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.160196","article-title":"High-throughput recombinant protein expression in Escherichia coli: current status and future perspectives","volume":"6","author":"Jia","year":"2016","journal-title":"Open Biol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0175","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41579-019-0243-0","article-title":"Protein post-translational modifications in bacteria","volume":"17","author":"Macek","year":"2019","journal-title":"Nat Rev Microbiol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004960","article-title":"Antigenic Variation of East\/Central\/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera","volume":"10","author":"Chua","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.vaccine.2020.01.091_b0185","doi-asserted-by":"crossref","first-page":"8879","DOI":"10.1128\/JVI.00370-12","article-title":"A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design","volume":"86","author":"Akahata","year":"2012","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0190","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1016\/j.vaccine.2009.02.090","article-title":"Immune interference after sequential alphavirus vaccine vaccinations","volume":"27","author":"Pittman","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.091_b0195","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/514240","article-title":"Immunologic interference from sequential administration of live attenuated alphavirus vaccines","volume":"177","author":"McClain","year":"1998","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.01.091_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008061","article-title":"Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins","volume":"15","author":"Quiroz","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2020.01.091_b0205","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw6647","article-title":"A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection","volume":"4","author":"Kose","year":"2019","journal-title":"Sci Immunol."},{"key":"10.1016\/j.vaccine.2020.01.091_b0210","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.chom.2015.06.009","article-title":"Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus","volume":"18","author":"Smith","year":"2015","journal-title":"Cell Host Microbe."},{"key":"10.1016\/j.vaccine.2020.01.091_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005637","article-title":"Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques","volume":"11","author":"Broeckel","year":"2017","journal-title":"PLoS Negl Trop Dis."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20301444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20301444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:40:01Z","timestamp":1759401601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20301444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0264410X20301444"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.091","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacteriophage Q\u03b2 virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}